Evaluation of Clinical efficacy of Uraimathirai as Immunomodulator

CENTRAL COUNCIL FOR RESEARCH IN SIDDHA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

研究概览

暂无简介。

•Children of either gender aged 6 MONTHS to 6 Years with a history of recurrent URTIs and presenting with URTI at hospital treatment.
•The definition used for recurrent URTIs was three or more such episodes during the last 12 months.
•The current episode required for study eligibility was
•Defined by the presence of at least two of the following
•Pharyngitis
•hoarseness,
•Temperature More than 38.5Ã?Â°C,
•Prescription of an antibiotic for a URTI, occurring after an asymptomatic Period of at least 1 week without antibiotics

•occurrence of otitis media and/or sinusitis and/or
•infection of the lower respiratory tract (ie, bronchitis, pneumonia)and/or proven group A streptococcal angina at the enrollment
•Further main exclusion criteria were allergic asthma,
•significant systemic disease (eg, hepatic and/or
•renal disease, malignancy), immune system disorders, suspected
•Malabsorption, major surgical procedure within 3 months of commencement of the study
•recent immunosuppressive or immunostimulant therapy, or corticosteroids.

发起方

CENTRAL COUNCIL FOR RESEARCH IN SIDDHA